HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

Frank Alexis; Pamela Basto; Etgar Levy-Nissenbaum; Aleksandar F. Radovic-Moreno; Liangfang Zhang; Eric Pridgen; Andrew Z. Wang; Shawn L. Marein; Katrina Westerhof; Linda K. Molnar; Omid C. Farokhzad

doi:10.1002/cmdc.200800122

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

Frank Alexis, Pamela Basto, Etgar Levy-Nissenbaum, Aleksandar F. Radovic-Moreno, Liangfang Zhang, Eric Pridgen, Andrew Z. Wang, Shawn L. Marein, Katrina Westerhof, Linda K. Molnar, Omid C. Farokhzad

Research output: Contribution to journal › Article › peer-review

140 Scopus citations

Abstract

(Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.

Original language	English (US)
Pages (from-to)	1839-1843
Number of pages	5
Journal	ChemMedChem
Volume	3
Issue number	12
DOIs	https://doi.org/10.1002/cmdc.200800122
State	Published - Dec 15 2008
Externally published	Yes

Keywords

Affibodies
Antitumor agents
Nanoparticles
PLA-PEG copolymers
Targeted therapy

ASJC Scopus subject areas

Drug Discovery
General Pharmacology, Toxicology and Pharmaceutics
Molecular Medicine
Biochemistry
Pharmacology
Organic Chemistry

Access to Document

10.1002/cmdc.200800122

Cite this

@article{4d14e98cf198495cb5b3ac97417d252c,

title = "HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy",

abstract = "(Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.",

keywords = "Affibodies, Antitumor agents, Nanoparticles, PLA-PEG copolymers, Targeted therapy",

author = "Frank Alexis and Pamela Basto and Etgar Levy-Nissenbaum and Radovic-Moreno, {Aleksandar F.} and Liangfang Zhang and Eric Pridgen and Wang, {Andrew Z.} and Marein, {Shawn L.} and Katrina Westerhof and Molnar, {Linda K.} and Farokhzad, {Omid C.}",

year = "2008",

month = dec,

day = "15",

doi = "10.1002/cmdc.200800122",

language = "English (US)",

volume = "3",

pages = "1839--1843",

journal = "ChemMedChem",

issn = "1860-7179",

publisher = "John Wiley and Sons Ltd",

number = "12",

}

TY - JOUR

T1 - HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

AU - Alexis, Frank

AU - Basto, Pamela

AU - Levy-Nissenbaum, Etgar

AU - Radovic-Moreno, Aleksandar F.

AU - Zhang, Liangfang

AU - Pridgen, Eric

AU - Wang, Andrew Z.

AU - Marein, Shawn L.

AU - Westerhof, Katrina

AU - Molnar, Linda K.

AU - Farokhzad, Omid C.

PY - 2008/12/15

Y1 - 2008/12/15

N2 - (Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.

AB - (Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). We developed drug delivery vehicles composed of polymeric NPs surface modified with affibody ligands that bind the extracellular domain of the human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells that overexpress the HER-2 antigen.

KW - Affibodies

KW - Antitumor agents

KW - Nanoparticles

KW - PLA-PEG copolymers

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=57549090074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57549090074&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200800122

DO - 10.1002/cmdc.200800122

M3 - Article

C2 - 19012296

AN - SCOPUS:57549090074

SN - 1860-7179

VL - 3

SP - 1839

EP - 1843

JO - ChemMedChem

JF - ChemMedChem

IS - 12

ER -

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this